The Business Research Company’s report on the Kidney Cancer Diagnostics And Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the kidney cancer diagnostics and therapeutics industry?
The increasing prevalence of kidney cancer is expected to drive the growth of kidney cancer diagnostics and therapeutics market. Kidney cancer refers to a condition that originates when the normal cells in one or both kidneys undergo abnormal changes and exhibit uncontrolled growth, resulting in the formation of a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer play a crucial role in the management and treatment of the disease, offering several benefits for patients. offer several benefits in the management of kidney cancer, such as early detection, accurate diagnosis, treatment selection, personalized medicine, and treatment monitoring. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization working for cancer care, in the United States, kidney cancer will be discovered in 81,800 individuals in 2023 (52,360 males and 29,440 women). And in 2020, kidney cancer will have affected 431,288 individuals globally. Therefore, the increasing prevalence of kidney cancer is expected to propel the growth of kidney cancer diagnostics and therapeutics market.
Access Your Free Sample of the Global Kidney Cancer Diagnostics And Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
What is the estimated market size of the kidney cancer diagnostics and therapeutics sector by 2029, based on current forecasts?
The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $4.1 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements
The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11937&type=smp
#Who are the top players in the kidney cancer diagnostics and therapeutics market?
Major companies operating in the kidney cancer diagnostics and therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited
#What are the major trends in the kidney cancer diagnostics and therapeutics market?
Major companies operating in kidney cancer diagnostics and therapeutics market are focusing on developing advanced renal cell carcinoma (RCC) to improve patient outcomes and provide innovative treatment options tailored to the specific needs of individuals diagnosed with this challenging disease. Research into renal cell carcinoma (RCC) is essential for kidney cancer diagnostics and therapeutics, as it drives the creation of innovative diagnostic methods and targeted therapies that improve early diagnosis and individualized treatment for patients. For instance, in December 2023, Merck, a US-based pharmaceutical company, launched welireg (belzutifan), the first hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor approved for adult patients with advanced renal cell carcinoma (RCC) after prior treatments with PD-1 or PD-L1 inhibitors and VEGF-TKIs. This novel therapeutic class shows significant benefits, including improved progression-free survival and higher response rates compared to everolimus. WELIREG’s approval represents a crucial advancement in the kidney cancer diagnostics and therapeutics market, offering new hope for patients with progressing disease.
Which geography holds the highest kidney cancer diagnostics and therapeutics market share?
North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the kidney cancer diagnostics and therapeutics market?
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma, Other Cancer Types
2) By Component: Drugs, Diagnostics
3) By Diagnostics: Biopsy, CT Scan, Nephro-Ureteroscopy, Intravenous Pyelogram, Ultrasound
4) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy
5) By End-Users: Hospitals, Pharmaceutical Labs, Genomics Laboratories
Subsegments:
1) By Clear Cell RCC: Stage I, Stage II, Stage III, Stage IV
2) By Papillary RCC: Type 1, Type 2
3) By Chromophobe RCC: Localized, Advanced
4) By Urothelial Carcinoma And Transitional Cell Carcinoma: Non-muscle invasive, Muscle invasive, Metastatic
5) By Other Cancer Types: Collecting Duct Carcinoma, Renal Medullary Carcinoma, Other rare types
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11937
How is the kidney cancer diagnostics and therapeutics market defined?
Kidney cancer diagnostics and therapeutics refer to a process of methods and treatments used for diagnosing and managing kidney cancer, also known as renal cell carcinoma. These approaches aim to detect the presence of kidney cancer, determine its stage and extent, and provide appropriate treatment options to manage the disease.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
